Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVTENASDAQ:CUENASDAQ:GNFTNASDAQ:TVGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVTEAerovate Therapeutics$7.25-1.6%$53.05$43.75▼$884.98$210.14M0.9518,765 shs504,908 shsCUECue Biopharma$0.64+2.1%$0.76$0.45▼$1.99$48.53M1.51427,323 shs97,140 shsGNFTGenfit$4.41+2.2%$3.80$2.55▼$6.42$220.23M0.9214,499 shs4,105 shsTVGNTevogen Bio$1.34+2.3%$1.09$0.26▼$3.09$240.90M-0.825.00 million shs416,553 shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVTEAerovate Therapeutics-1.63%-3.20%+171.03%-91.48%-98.78%CUECue Biopharma+2.14%-8.92%-15.77%-47.64%-59.24%GNFTGenfit+2.20%+1.50%+8.63%+26.95%-15.77%TVGNTevogen Bio+2.29%+8.94%+32.67%+4.69%+68.13%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVTEAerovate Therapeutics1.5425 of 5 stars3.00.00.00.03.21.70.6CUECue Biopharma4.2299 of 5 stars3.52.00.04.73.30.81.3GNFTGenfit2.1798 of 5 stars3.55.00.00.02.10.00.0TVGNTevogen Bio3.7876 of 5 stars3.54.00.00.02.02.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVTEAerovate Therapeutics 2.00Hold$78.75986.21% UpsideCUECue Biopharma 3.00Buy$3.00365.84% UpsideGNFTGenfit 3.00Buy$13.00195.12% UpsideTVGNTevogen Bio 3.00Buy$7.10429.85% UpsideCurrent Analyst Ratings BreakdownLatest CUE, AVTE, TVGN, and GNFT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2025TVGNTevogen BioD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.005/12/2025TVGNTevogen BioD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.004/29/2025TVGNTevogen BioD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.004/21/2025TVGNTevogen BioD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/11/2025TVGNTevogen BioD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/4/2025TVGNTevogen BioD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$10.00(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVTEAerovate TherapeuticsN/AN/AN/AN/A$3.96 per shareN/ACUECue Biopharma$7.99M6.07N/AN/A$0.82 per share0.79GNFTGenfit$67.00M3.29N/AN/A$1.48 per share2.98TVGNTevogen BioN/AN/AN/AN/A($1.10) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVTEAerovate Therapeutics-$75.52M-$1.70N/AN/AN/AN/A-90.19%-77.47%8/11/2025 (Estimated)CUECue Biopharma-$50.73M-$0.67N/AN/AN/A-468.02%-156.38%-88.07%8/13/2025 (Estimated)GNFTGenfit-$31.27MN/A0.00N/AN/AN/AN/AN/AN/ATVGNTevogen Bio-$70KN/A0.00∞N/AN/A-396.07%749.97%N/ALatest CUE, AVTE, TVGN, and GNFT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025CUECue Biopharma-$0.14-$0.17-$0.03-$0.17$0.90 million$0.42 million4/25/2025Q4 2024AVTEAerovate Therapeutics-$10.50-$3.15+$7.35-$0.09N/AN/A3/28/2025Q4 2024CUECue Biopharma-$0.14-$0.13+$0.01-$0.13$1.70 million$1.80 million3/27/2025Q4 2024AVTEAerovate Therapeutics-$6.65-$6.65N/A-$0.19N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVTEAerovate TherapeuticsN/AN/AN/AN/AN/ACUECue BiopharmaN/AN/AN/AN/AN/AGNFTGenfitN/AN/AN/AN/AN/ATVGNTevogen BioN/AN/AN/AN/AN/ALatest CUE, AVTE, TVGN, and GNFT DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/9/2025AVTEAerovate Therapeutics$84.004/29/20254/25/20254/28/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVTEAerovate TherapeuticsN/A8.788.78CUECue Biopharma0.052.222.22GNFTGenfit0.613.743.74TVGNTevogen BioN/A0.340.34Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVTEAerovate TherapeuticsN/ACUECue Biopharma35.04%GNFTGenfit2.24%TVGNTevogen BioN/AInsider OwnershipCompanyInsider OwnershipAVTEAerovate Therapeutics24.90%CUECue Biopharma10.78%GNFTGenfit4.20%TVGNTevogen Bio73.24%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVTEAerovate Therapeutics2028.99 million21.69 millionOptionableCUECue Biopharma6075.35 million55.58 millionOptionableGNFTGenfit12050.00 million47.90 millionNot OptionableTVGNTevogen Bio3183.89 million75.97 millionN/ACUE, AVTE, TVGN, and GNFT HeadlinesRecent News About These CompaniesTevogen Bio (NASDAQ:TVGN) Earns Buy Rating from D. Boral CapitalMay 29 at 1:15 AM | americanbankingnews.comTevogen Bio (NASDAQ:TVGN) Earns "Buy" Rating from D. Boral CapitalMay 28 at 8:15 AM | marketbeat.comTevogen Peports Plans to Increase the Target Population for TVGN 489May 26, 2025 | msn.comTevogen expands target for COVID treatment to seniorsMay 24, 2025 | investing.comTevogen Bio Inc: Tevogen Bio Plans to Expand Specialty Care Pipeline to Include Patients 65+, Building on Previous Forecast of Nearly $1 Billion in Launch-Year; Updated rNPV to ...May 24, 2025 | finanznachrichten.deTevogen breidt doelgroep voor COVID-behandeling uit naar 65-plussersMay 23, 2025 | nl.investing.comTevogen Bio Plans to Expand Specialty Care Pipeline to Include Patients 65+, Building on Previous Forecast of Nearly $1 Billion in Launch-Year; Updated rNPV to FollowMay 23, 2025 | globenewswire.comTevogen Bio Holdings Inc. to Provide Key Updates Ahead of Annual Meeting on June 23, 2025May 22, 2025 | quiverquant.comTevogen to Update on Robust Portfolio Assets, Business Expansion, Partnerships, Limited Tradable Float, High Insider Ownership and Strong Investor Confidence Ahead of June 23 Annual MeetingMay 22, 2025 | globenewswire.comD. Boral Capital Reiterates "Buy" Rating for Tevogen Bio (NASDAQ:TVGN)May 14, 2025 | marketbeat.comTevogen Bio Positions Itself as a Leader in Cost-Efficient Healthcare Amid Global Pharmaceutical CompetitionMay 13, 2025 | nasdaq.comTevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient InnovationMay 12, 2025 | globenewswire.comTevogen Bio Holdings Inc. Announces Letter of Intent with CD8 Technology Services for Cell Therapy Manufacturing FacilityMay 2, 2025 | nasdaq.comTevogen to Share Direct Registration System (DRS) Process Details Following Increased Shareholder InterestMay 2, 2025 | globenewswire.comD. Boral Capital Reaffirms "Buy" Rating for Tevogen Bio (NASDAQ:TVGN)May 1, 2025 | marketbeat.comCD8 Technology Signs Letter of Intent for Tevogen Bio’s In-House Manufacturing Facility, Marking First Phase of Up to $50 Million CommitmentApril 30, 2025 | uk.finance.yahoo.comWhy Tevogen Bio Holdings Inc.’s (TVGN) Stock Is Up 5.60%April 30, 2025 | aaii.comCD8 Technology Signs Letter of Intent for Tevogen Bio's In-House Manufacturing Facility, Marking First Phase of Up to $50 Million CommitmentApril 30, 2025 | globenewswire.comTevogen Bio shares surge on revenue forecastApril 29, 2025 | investing.comTevogen Informs Public Shareholders About DRS Accounts And Differences to Brokerage AccountsApril 29, 2025 | globenewswire.comTevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ's Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor FitzgeraldApril 29, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCUE, AVTE, TVGN, and GNFT Company DescriptionsAerovate Therapeutics NASDAQ:AVTE$7.25 -0.12 (-1.63%) As of 05/28/2025Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.Cue Biopharma NASDAQ:CUE$0.64 +0.01 (+2.14%) Closing price 05/29/2025 04:00 PM EasternExtended Trading$0.66 +0.01 (+2.17%) As of 05/29/2025 07:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.Genfit NASDAQ:GNFT$4.25 -0.06 (-1.37%) As of 05/29/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.Tevogen Bio NASDAQ:TVGN$1.34 +0.03 (+2.29%) Closing price 05/29/2025 04:00 PM EasternExtended Trading$1.33 -0.01 (-0.45%) As of 05:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Hormel Stock Near Lows, But Tariff Relief Could Boost Outlook Salesforce’s Stock Price Presents an Opportunity to Buy NVIDIA Will Set a New High Soon, Then Keep Rallying, Here’s Why Goodyear Stock Surges 28% in 2025: Is More Growth Ahead? Intel's Loss Is Broadcom's Gain as AVGO Dominates Networking Target's Big Bet: Is It a Cheap Stock or a Value Trap? Dividend Investors Looking for an Edge? 3 Stocks Insiders Bought Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
